Compare · APGE vs ARGX
APGE vs ARGX
Side-by-side comparison of Apogee Therapeutics Inc. (APGE) and argenx SE (ARGX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both APGE and ARGX operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- ARGX is the larger of the two at $53.41B, about 5.3x APGE ($10.10B).
- Over the past year, APGE is up 240.9% and ARGX is up 52.5% - APGE leads by 188.4 points.
- APGE has been more active in the news (18 items in the past 4 weeks vs 3 for ARGX).
- ARGX has more recent analyst coverage (25 ratings vs 19 for APGE).
- Company
- Apogee Therapeutics Inc.
- argenx SE
- Price
- $134.00-0.05%
- $861.30+0.30%
- Market cap
- $10.10B
- $53.41B
- 1M return
- +57.30%
- -1.91%
- 1Y return
- +240.88%
- +52.49%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2023
- 2017
- News (4w)
- 18
- 3
- Recent ratings
- 19
- 25
argenx SE
argenx SE, a clinical-stage biotechnology company, focuses on developing antibody-based therapies for the treatment of autoimmune diseases, hematology, and cancer. It is developing its lead product candidate, efgartigimod, for the treatment of patients with myasthenia gravis; immune thrombocytopenia in Phase III; pemphigus vulgaris in Phase III; chronic inflammatory demyelinating polyneuropathy in Phase III; and ENHANZE SC in pre-clinical stages. The company is also developing cusatuzumab in Phase II clinical stage in hematological cancer indications; ARGX-117 in phase I clinical trial with therapeutic potential in both orphan and large autoimmune inflammatory diseases; and preclinical products, including ARGX-118 for airway inflammation. Its partnered product candidates include ARGX-112 for treating skin inflammation, ARGX-116 for the treatment of dyslipidemia, and ARGX-115 for cancer immunotherapy, which are in Phase I clinical stages; and ARGX-114 for treating fibrosisand ARGX-119 for treating neuromuscular indications, which are in preclinical stage. The company has strategic partnership with AbbVie S.Ã.R.L. and LEO Pharma A/S; and collaboration agreement with Cilag GmbH International, Staten Biotechnology B.V., and Shire International GmbH. argenx SE was incorporated in 2008 and is based in Breda, the Netherlands.
Latest APGE
- Chief Medical Officer Dambkowski Carl gifted 8,000 shares, decreasing direct ownership by 4% to 169,873 units (SEC Form 4)
- SEC Form DEFM14A filed by Apogee Therapeutics Inc.
- Chief Executive Officer Henderson Michael Thomas sold $2,672,600 worth of shares (20,000 units at $133.63) as part of a pre-agreed trading plan and gifted 75,046 shares, decreasing direct ownership by 9% to 920,941 units (SEC Form 4)
- Amendment: SEC Form SCHEDULE 13G/A filed by Apogee Therapeutics Inc.
- Amendment: SEC Form SCHEDULE 13G/A filed by Apogee Therapeutics Inc.
- Amendment: SEC Form SCHEDULE 13G/A filed by Apogee Therapeutics Inc.
- Chief Medical Officer Dambkowski Carl sold $730,070 worth of shares (5,500 units at $132.74) as part of a pre-agreed trading plan and exercised 4,125 shares at a strike of $22.86, decreasing direct ownership by 0.77% to 177,873 units (SEC Form 4)
- SEC Form PREM14A filed by Apogee Therapeutics Inc.
- SEC Form DEFA14A filed by Apogee Therapeutics Inc.
- Chief Medical Officer Dambkowski Carl sold $3,500,640 worth of shares (26,400 units at $132.60) as part of a pre-agreed trading plan, decreasing direct ownership by 13% to 179,248 units (SEC Form 4)
Latest ARGX
- argenx to Report Half Year 2026 Financial Results and Second Quarter Business Update on July 23, 2026
- SEC Form 6-K filed by argenx SE
- argenx to Host Autoimmune Myositis R&D Webinar
- SEC Form 6-K filed by argenx SE
- argenx Presents New Efgartigimod Data Showing Long-Term Sustained Patient Benefit in Myositis and Sjogren's Disease at EULAR 2026
- argenx to Host Myositis R&D Webinar on June 23, 2026
- argenx to Present at Upcoming Investor Conferences
- The Biology Came First.
- SEC Form 6-K filed by argenx SE
- argenx Announces U.S. FDA Approval Expanding VYVGART and VYVGART Hytrulo for Use in All Adult Patients Living with gMG